Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units Through Savings Plan

Pfizer's CEO, Albert Bourla, acquired 21 phantom stock units through the company's Supplemental Savings Plan, as detailed in a recent SEC filing.

Summary

• Albert Bourla, the CEO of Pfizer, acquired 21 phantom stock units on December 13, 2024, through the company's Supplemental Savings Plan.
• These units are equivalent to shares of common stock but are settled in cash upon the CEO's separation from service.
• The units can be transferred into an alternative investment account at any time by Mr. Bourla.
• Following this transaction, Mr. Bourla beneficially owns 690,626 shares of Pfizer stock.
• The transaction was reported in a Form 4 filing with the SEC.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally. The acquisition of phantom stock units is a positive sign of alignment with company performance, but it is not a major event.

Positives

• The acquisition of phantom stock units through the savings plan aligns the CEO's interests with the long-term performance of the company.
• The ability to transfer the units into an alternative investment account provides flexibility for the CEO.

Industry Context

This type of transaction is common for executives at publicly traded companies, as it is a way to provide compensation that is tied to the company's performance. It is a standard practice for companies to offer supplemental savings plans to their executives.

Comparison to Industry Standards

• Many large pharmaceutical companies use similar stock-based compensation plans for their executives, including phantom stock units, restricted stock, and stock options.
• Companies like Johnson & Johnson, Merck, and AbbVie also utilize similar plans to align executive interests with shareholder value.
• The use of phantom stock units is a common practice to provide deferred compensation that is tied to the company's stock performance without issuing new shares.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the CEO's interests with the company's performance.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Pfizer, Albert Bourla, phantom stock units, SEC Form 4, Supplemental Savings Plan, executive compensation, insider trading